ISSN: 1198-0052

Journal Home

Journal Guideline

Current Oncology Q2 Unclaimed

Multidisciplinary Digital Publishing Institute (MDPI) Canada

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Current Oncology is a journal indexed in SJR in Oncology with an H index of 55. It has a price of 2100 €. It has a best quartile of Q2. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Oncology (Q2)

Price

2100 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

-

SJR Impact factor

55

H Index

455

Total Docs (Last Year)

484

Total Docs (3 years)

19553

Total Refs

1558

Total Cites (3 years)

433

Citable Docs (3 years)

2.63

Cites/Doc (2 years)

42.97

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

International Journal of Oncology Q2
BMC Cancer Q2
Cancer Epidemiology Q2
Frontiers in Oncology Q2
Journal of Geriatric Oncology Q2

Compare this journals

Aims and Scope

Best articles by citations

Re-irradiation of metastatic disease in the neck from xeroderma pigmentosum

Predictors of immunotherapy-induced immune-related adverse events

Residual cancer burden in locally advanced breast cancer: a superior tool

Benefits, issues, and recommendations for personalized medicine in oncology in Canada

Terry Fox's legacy: a case for translational research

Countercurrents: The bias of choice

Challenging obesity relating to Barrett esophagitis

Multidisciplinary management of cancer patients: chasing a shadow or real value? An overview of the literature

In this issue of Current Oncology

Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018

Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis

Author Index

SHOW MORE ARTICLES

Secondary polycythemia in a sarcoma patient: a commentary about cediranib

Initial McGill experience with fluorodeoxyglucose PET/CT staging of soft-tissue sarcoma

An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction

Arterial occlusion precipitated by cisplatin-based chemotherapy

Development of an online, patient-centred decision aid for patients with oropharyngeal cancer in the transoral robotic surgery era

African-Caribbean Cancer Consortium Scientific and Training Conference 2017rence 2017 Meeting Report

Erratum: Current and emerging biomarkers in metastatic colorectal cancer

Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification

Small Molecule Bcl-2 Antagonists as Targeted Therapy in Oncology

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

The Terry Fox Research Institute's West Coast Dialogue: are we prepared for personalized medicine?

Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study